Probiotics in Pediatrics

Presenting global evidence for their utility in children, Prof. Sherman illustrated that evidence through randomized controlled trails have demonstrated that certain probiotic strains are more effective than placebo in a variety of conditions affecting the gastrointestinal tract. Multiple meta-analyses indicate effectiveness in reducing the duration of acute enteritis in pre-schoolers and in reducing the frequency of necrotizing enterocolitis in pre-term babies. As probiotics exist naturally in some foods and are also available as dietary supplements in powder, capsule, and tablet forms. In 2002, the industry secured FDA designation of specific strains of B. lactis and Streptococcus thermophilus as substances generally recognized as safe (GRAS) in milk-based formulas for infants aged 4 months and older. Most probiotic bacteria are similar to the beneficial bacteria that occur naturally in the gut, including those of the Lactobacillus species (eg, L. acidophilus). Infants acquire other bacteria during their first months, mainly those of the Bifidobacterium and Enterobacter species. Bifidobacterium species dominate in the gut of breast-fed infants, whereas Enterobacter microbes dominate in bottle-fed infants. This difference in species, which has been identified as key to breast-fed infants’ superior immunity to many infections, has spurred much of the medical and pediatric communities’ interest in probiotics. Infant formula manufacturers have also taken interest

  • Intestinal health maintenance
  • Milk based microbiota
  • Probiotics use in malnutrition
  • Infant gut infection prevention
  • Infant immune system stimulation
  • Infant immune system stimulation
  • Infants Allergic reaction prevention
  • Formula infants: Growth and development
  • Probiotics in Pediatric illness
  • Probiotics in Pediatric Medicine

Probiotics in Pediatrics Conference Speakers

Recommended Sessions

Related Journals

Are you interested in